Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.62 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12693654 | 1.00 | LPL (0.62) | LPLLIPGTAAR1DRD2SLC6A4 | |
| SCHEMBL19540034 | 1.00 | LPL (0.62) | LPLLIPGTAAR1DRD2SLC6A4 | |
| SCHEMBL12693653 | 0.98 | LPL (0.61) | LPLLIPGTAAR1DRD2SLC6A4 | |
| Ethyne SCHEMBL27743291 | 0.94 | LPL (0.57) | LPLLIPGTAAR1DRD2SLC6A4 | |
| SCHEMBL1056081 | 0.92 | TAAR1 (0.59) | LPLLIPGTAAR1DRD2SLC6A4 | |
| Ethane SCHEMBL28237447 | 0.90 | TAAR1 (0.57) | LPLLIPGTAAR1DRD2SLC6A4 | |
| Formic Acid SCHEMBL27941404 | 0.88 | LPL (0.55) | LPLLIPGTAAR1DRD2SLC6A4 | |
| SCHEMBL28050134 | 0.88 | LPL (0.51) | LPLLIPGTAAR1DRD2SLC6A4 | |
| Fluorobenzene SCHEMBL28299508 | 0.87 | LPL (0.57) | LPLLIPGTAAR1DRD2PPARG | |
| SCHEMBL29742685 | 0.86 | LPL (0.67) | LPLLIPGSLC6A4SLC6A3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10780092-B2 | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190307753-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307753-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | PDE2A, PDE3A, PDE5A | LPL 1668/4885LIPG 2160/4885TAAR1 1129/4885 |
| US-10780092-B2 | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators | PDE2A, PDE3A, PDE5A | LPL 1627/4885LIPG 2047/4885TAAR1 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.